Longitudinal plasma proteomics reveals two distinct molecular dimensions of progression and prognosis in Small cell lung cancer
Small cell lung cancer (SCLC) frequently develops resistance to platinum-based chemotherapy, which contributes to poor survival. Resistance-associated biological changes remain poorly characterized, and their distinction from intrinsic prognostic factors is unclear, hindering the development of biomarker-guided therapeutic strategies. We conducted a retrospective, longitudinal plasma proteomic study in 43 patients with SCLC at baseline and at the time of radiographically confirmed treatment resistance (RECIST-defined progression). We examined plasma proteomic changes associated with resistance. Cox regression and LASSO analyses were performed using baseline proteomics to identify prognostic markers. We identified 27 significantly differentially expressed plasma proteins (DEPs) (adjusted p value < 0.05) between baseline and resistance timepoints (23 upregulated and 4 downregulated). Immune checkpoint proteins (e.g. PD-L1) and growth factors (e.g. FGF-21) were markedly upregulated, whereas differentiation markers (e.g. CRNN) were markedly downregulated. Functional enrichment analysis suggested that these DEPs are associated with cell adhesion, RTK signaling, and immune microenvironment remodeling. Importantly, the baseline prognostic power of these 27 resistance-associated DEPs was limited (all Cox p > 0.05). Using baseline proteomic data from the same cohort, LASSO-Cox analysis identified a 5-protein prognostic signature (XPNPEP2, ACAA1, APLP1, NT5E, and SCF) associated with baseline prognosis. This exploratory study identifies 27 plasma proteins with candidate associations to treatment resistance, and a 5-protein prognostic signature associated with baseline survival in SCLC. These findings are hypothesis-generating and require external validation before clinical application; the identified proteins represent candidate biomarkers and potential avenues for future mechanistic investigation, rather than validated therapeutic targets.
Authors
- Jiao Wu (ORCID: https://orcid.org/0000-0002-9718-5499)
- Runxiang Yang (ORCID: https://orcid.org/0000-0003-3684-5892)
- Chunxiang Luo
- Lijuan Cai
- Xiang Li
- Fang Yang
Institutions
- Kunming Medical University (CN)
Publication Details
- Journal
- Clinical Proteomics
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1186/s12014-026-09653-w
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00